Valuation Update With 7 Day Price Move • Jul 21
Investor sentiment improves as stock rises 31% After last week's 31% share price gain to ₹62.00, the stock trades at a trailing P/E ratio of 16x. Average trailing P/E is 22x in the Chemicals industry in India. Total returns to shareholders of 13% over the past year. Valuation Update With 7 Day Price Move • Jul 07
Investor sentiment improves as stock rises 17% After last week's 17% share price gain to ₹50.40, the stock trades at a trailing P/E ratio of 13x. Average trailing P/E is 21x in the Chemicals industry in India. Total loss to shareholders of 4.5% over the past year. Reported Earnings • May 28
Full year 2026 earnings released: EPS: ₹3.79 (vs ₹3.44 in FY 2025) Full year 2026 results: EPS: ₹3.79 (up from ₹3.44 in FY 2025). Revenue: ₹2.09b (up 4.2% from FY 2025). Net income: ₹66.4m (up 13% from FY 2025). Profit margin: 3.2% (up from 2.9% in FY 2025). The increase in margin was driven by higher revenue. New Risk • May 26
New minor risk - Share price stability The company's share price has been volatile over the past 3 months. It is more volatile than 75% of Indian stocks, typically moving 8.7% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Major Risks Interest payments are not well covered by earnings (2.5x net interest cover). Market cap is less than US$10m (₹757.6m market cap, or US$7.92m). Minor Risk Share price has been volatile over the past 3 months (8.7% average weekly change). Ankündigung • May 22
Crop Life Science Limited to Report Second Half, 2026 Results on May 26, 2026 Crop Life Science Limited announced that they will report second half, 2026 results on May 26, 2026 New Risk • Apr 22
New minor risk - Share price stability The company's share price has been volatile over the past 3 months. It is more volatile than 75% of Indian stocks, typically moving 8.9% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Major Risks Interest payments are not well covered by earnings (2.5x net interest cover). Market cap is less than US$10m (₹758.4m market cap, or US$8.10m). Minor Risk Share price has been volatile over the past 3 months (8.9% average weekly change). Board Change • Jan 01
Insufficient new directors No new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 4 experienced directors. 2 highly experienced directors. Non-Executive Independent Director Parulben Shah was the last director to join the board, commencing their role in 2022. The company’s insufficient board refreshment is considered a risk according to the Simply Wall St Risk Model. New Risk • Nov 27
New major risk - Market cap size The company's market capitalization is less than US$10m. Market cap: ₹891.3m (US$9.97m) This is considered a major risk. Companies with a small market capitalization are most likely businesses that have not yet released a product to market or are simply a very small company without a wide reach. Either way, risk is elevated with these companies because there is a chance the product may not come to fruition or the company's addressable market or demand may not be as large as expected. In addition, if the company's size is the main factor, it is less likely to have many investors and analysts following it and scrutinizing its performance and outlook. Currently, the following risks have been identified for the company: Major Risks Interest payments are not well covered by earnings (2.5x net interest cover). Market cap is less than US$10m (₹891.3m market cap, or US$9.97m). Ankündigung • Nov 07
Crop Life Science Limited to Report First Half, 2026 Results on Nov 12, 2025 Crop Life Science Limited announced that they will report first half, 2026 results on Nov 12, 2025 Ankündigung • Aug 28
Crop Life Science Limited, Annual General Meeting, Sep 26, 2025 Crop Life Science Limited, Annual General Meeting, Sep 26, 2025, at 15:30 Indian Standard Time. New Risk • Jun 10
New minor risk - Share price stability The company's share price has been volatile over the past 3 months. It is more volatile than 75% of Indian stocks, typically moving 8.0% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Major Risk Interest payments are not well covered by earnings (2.6x net interest cover). Minor Risks Latest financial reports are more than 6 months old (reported September 2024 fiscal period end). Share price has been volatile over the past 3 months (8.0% average weekly change). Profit margins are more than 30% lower than last year (2.6% net profit margin). Market cap is less than US$100m (₹860.4m market cap, or US$10.1m). New Risk • Jun 02
New minor risk - Financial data availability The company's latest financial reports are more than 6 months old. Last reported fiscal period ended September 2024. This is considered a minor risk. If the company has not reported its earnings on time, it may have been delayed due to audit problems or it may be finding it difficult to reconcile its accounts. Currently, the following risks have been identified for the company: Major Risks Interest payments are not well covered by earnings (2.6x net interest cover). Market cap is less than US$10m (₹836.4m market cap, or US$9.80m). Minor Risks Latest financial reports are more than 6 months old (reported September 2024 fiscal period end). Profit margins are more than 30% lower than last year (2.6% net profit margin). New Risk • Apr 17
New minor risk - Share price stability The company's share price has been volatile over the past 3 months. It is more volatile than 75% of Indian stocks, typically moving 8.7% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Major Risks Interest payments are not well covered by earnings (2.6x net interest cover). Market cap is less than US$10m (₹808.2m market cap, or US$9.46m). Minor Risks Share price has been volatile over the past 3 months (8.7% average weekly change). Profit margins are more than 30% lower than last year (2.6% net profit margin). Ankündigung • Jan 23
Crop Life Science Limited Announces Resignation of Sunita Sebastian Gonsalves as Chief Financial Officer, Effective from February 08, 2025 Crop Life Science Limited announced that Mrs. Sunita Sebastian Gonsalves, Chief Financial Officer (CFO) & Key Managerial Personnel (KMP) of the company has tendered her resignation vide letter dated January 22, 2025, due to personal reasons and she will be relived from her duties effective from February 08, 2025 after the closing of business hours. New Risk • Nov 16
New minor risk - Profit margin trend The company's profit margins are lower than last year and have reduced by more than 30%. Net profit margin: 2.6% Last year net profit margin: 4.3% This is considered a minor risk. A large drop in profit margin could indicate the company does not have strong competitive advantages or it is yet to establish itself and its core business. Even if it is a well established business, this may make it a much riskier investment than one that has a combination of proven competitive advantages and a stable or growing profit margin. Currently, the following risks have been identified for the company: Major Risks Interest payments are not well covered by earnings (2.3x net interest cover). Share price has been highly volatile over the past 3 months (10% average weekly change). Market cap is less than US$10m (₹805.6m market cap, or US$9.54m). Minor Risk Profit margins are more than 30% lower than last year (2.6% net profit margin). New Risk • Oct 08
New major risk - Market cap size The company's market capitalization is less than US$10m. Market cap: ₹815.0m (US$9.71m) This is considered a major risk. Companies with a small market capitalization are most likely businesses that have not yet released a product to market or are simply a very small company without a wide reach. Either way, risk is elevated with these companies because there is a chance the product may not come to fruition or the company's addressable market or demand may not be as large as expected. In addition, if the company's size is the main factor, it is less likely to have many investors and analysts following it and scrutinizing its performance and outlook. Currently, the following risks have been identified for the company: Major Risks Interest payments are not well covered by earnings (2.8x net interest cover). Share price has been highly volatile over the past 3 months (11% average weekly change). High level of non-cash earnings (26% accrual ratio). Market cap is less than US$10m (₹815.0m market cap, or US$9.71m). Ankündigung • Sep 13
Crop Life Science Limited Announces Appointment of Miteshkumar Jayrambhai Rajgor as Company Secretary Crop Life Science Limited informed to the Stock Exchange that Mr. Miteshkumar Jayrambhai Rajgor has been appointed as Company Secretary and Compliance Officer of the Company with effect from 12th September, 2024. The particulars of the appointment of Mr. Miteshkumar Jayrambhai Rajgor as Company Secretary and Compliance Officer of the Company are as under: Brief profile: PAN: EIOPR6997H. Dare of Birth: July 10,1997. Membership No. ACS 70993. Nature of expertise: Secretarial Work. Valuation Update With 7 Day Price Move • Aug 22
Investor sentiment improves as stock rises 15% After last week's 15% share price gain to ₹53.55, the stock trades at a trailing P/E ratio of 15.2x. Average trailing P/E is 35x in the Chemicals industry in India. Ankündigung • Aug 21
Crop Life Science Limited, Annual General Meeting, Sep 21, 2024 Crop Life Science Limited, Annual General Meeting, Sep 21, 2024, at 15:30 Indian Standard Time. Ankündigung • Jul 31
Crop Life Science Limited Appoints Ashish Mahendersingh Chaudhary as Company Secretary and Compliance Officer Crop Life Science Limited appointed Ms. Ashish Mahendersingh Chaudhary has been appointed as Company Secretary and Compliance Officer of the Company, effective from July 31, 2024. Date of Birth: 08/06/1999. Reported Earnings • May 29
Full year 2024 earnings released: EPS: ₹4.02 (vs ₹3.39 in FY 2023) Full year 2024 results: EPS: ₹4.02 (up from ₹3.39 in FY 2023). Revenue: ₹2.01b (up 52% from FY 2023). Net income: ₹60.4m (up 48% from FY 2023). Profit margin: 3.0% (down from 3.1% in FY 2023). The decrease in margin was driven by higher expenses. Valuation Update With 7 Day Price Move • Apr 03
Investor sentiment improves as stock rises 16% After last week's 16% share price gain to ₹43.00, the stock trades at a trailing P/E ratio of 15.5x. Average trailing P/E is 29x in the Chemicals industry in India. Valuation Update With 7 Day Price Move • Mar 13
Investor sentiment deteriorates as stock falls 17% After last week's 17% share price decline to ₹38.25, the stock trades at a trailing P/E ratio of 13.8x. Average trailing P/E is 28x in the Chemicals industry in India. New Risk • Mar 01
New minor risk - Financial data availability The company's latest financial reports are more than 6 months old. Last reported fiscal period ended February 2023. This is considered a minor risk. If the company has not reported its earnings on time, it may have been delayed due to audit problems or it may be finding it difficult to reconcile its accounts. Currently, the following risks have been identified for the company: Major Risks Debt is not well covered by operating cash flow (3.7% operating cash flow to total debt). Market cap is less than US$10m (₹781.6m market cap, or US$9.43m). Minor Risk Latest financial reports are more than 6 months old (reported February 2023 fiscal period end). Valuation Update With 7 Day Price Move • Dec 27
Investor sentiment improves as stock rises 17% After last week's 17% share price gain to ₹48.80, the stock trades at a trailing P/E ratio of 17.6x. Average trailing P/E is 30x in the Chemicals industry in India. Ankündigung • Nov 22
Crop Life Science Limited, Annual General Meeting, Dec 13, 2023 Crop Life Science Limited, Annual General Meeting, Dec 13, 2023, at 11:00 Indian Standard Time. Location: 209, Primate, Near Judges Bunglow Cross Road Bodakdev Ahmedabad India Agenda: To receive,consider and adopt the Audited Standalone Financial Statement of the Company for the Financial Year ended 31st March, 2023 together with report of the Board of Directors & Auditors thereon; to appoint a Director in place of Mr. Chunilal Samajubhai Virolia; to consider and if thought fit to pass the following resolution with or without modification as Special Resolution; to ratify the remuneration of the Cost Auditors for the financial year ending March 31st, 2024; to approve to make investments, give loans, guarantees and provide securities under Section 186 of the Companies Act, 2013; to approve transactions under Section 185 of the Companies Act, 2013; and to Related Party Transaction for The Financial Year 2023-24. Ankündigung • Aug 31
Crop Life Science Limited has completed an IPO in the amount of INR 267.28 million. Crop Life Science Limited has completed an IPO in the amount of INR 267.28 million.
Security Name: Equity Shares
Security Type: Common Stock
Securities Offered: 2,440,000
Price\Range: INR 52
Discount Per Security: INR 0.4888
Security Name: Equity Shares
Security Type: Common Stock
Securities Offered: 260,000
Price\Range: INR 52
Discount Per Security: INR 0.4888
Security Name: Equity Shares
Security Type: Common Stock
Securities Offered: 2,440,000
Price\Range: INR 52
Discount Per Security: INR 0.4888
Transaction Features: Regulation S